Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Spartrapon Jun 25, 2020 12:16pm

127 Views

Post# 31190840

RE:Suggestion for Thera

not a big fan of radionucleides in conjugates.. the supply chain is a nightmare to setup with elements having a half-life of a week or so. And safety is..eeww.. adverse events are aplasia, secondary blood cancers due to radiations? wow. The patient is cured, too bad he is also soon to be dead.

Lutathera might be a relative success with all the BP muscle, a $400M/yr drug for Novartis up to now so not bad, but it's rather the exception. Those drug are mighty hard to develop. See ATNM and SESN.

Bullboard Posts

New Pacific Metals delivers robust Silver Sand pre-feasibility study